Fighting the COVID-19 pandemic requires an arsenal of research tools and reagents. RayBiotech provides the most complete and comprehensive range of products and services to support your efforts in SARS-CoV-2 research and development of therapies and vaccines.
For researchers and health professionals needing lab facilities or additional expertise, RayBiotech offers contract research services to help reach your objectives faster. In the webpage below, the symbol indicates products for which we offer full testing or custom service.
COVID-19 Collaborations: Collaborate with RayBiotech to advance COVID-19 research.
RayBiotech offers lateral flow devices for the detection of IgG and IgM antibodies to the coronavirus N-protein in serum, plasma, and peripheral blood. An example of a lateral flow device is a home pregnancy test. They are easy to use and provide rapid results.
Detect IgG antibodies to SARS-CoV-2 N and S1 RBD proteins in serum samples using the RayBio® COVID-19 Indirect ELISA kits.
The spike protein (S-protein) and nucleocapsid protein (N-protein) are encoded by all coronaviruses, including SARS-CoV-2 that was first detected in Wuhan City, China, in December 2019. Both recombinant forms of these proteins are now available from RayBiotech to advance infectious disease research.
Monoclonal & Polyclonal Antibodies to SARS-CoV-2
80 tests. Suitable for the qualitative in vitro detection of novel coronavirus (SARS-CoV-2 / COVID-19) nucleic acid in sera and respiratory specimens (including pharyngeal swabs).
20 tests. Suitable for the qualitative detection of new coronavirus (SARS-CoV-2 / COVID-19) nucleocapsid protein N gene in human throat swabs. Includes a one-step RT-qPCR mix. Conforms to CDC guidelines. LDT ready for high complexity CLIA labs.
25, 100, or 500 tests. No PCR instrument required! Suitable for the qualitative detection of SARS-CoV-2 virus in human throat swabs. Results detected by eye or plate reader.
Serum and plasma (EDTA) from normal (non-COVID-19) and COVID-19 patients.
Saliva and dried blood sample collection kits for RNA, DNA, Antibody and Protein analysis in normal (non-COVID-19) and COVID-19 patients.
The entry of the SARS-CoV-2 virus into host cell is mediated by an interaction between the Spike (S) protein’s receptor binding domain (RBD) on the surface of the viral particle and the Angiotensin I Converting Enzyme 2 (ACE2) receptor on the human cell surface. As such, this binding event is a biological target for COVID-19 therapies. The RayBio® COVID-19 Spike-ACE2 binding assay kit allows the researcher to rapidly screen and identify small molecules, antibodies, or other biological molecules that potentially interfere with the formation of the S-ACE2 complex.
Antibody screening has important public health uses in determining immunity to and prevalence of COVID-19, as well as identifying who has been infected and evaluating potential blood based therapeutics. Detect IgG, IgM, and IgA antibodies to SARS-CoV-2 N and S1 RBD proteins in serum and dried blood samples using the indirect ELISA kits. Additionally, use the sandwich ELISAs for detecting N- and S-Proteins
Semi-quantitative detection of IgM and IgG antibodies in serum or plasma to the SARS-CoV-2 (COVID-19) spike (S) protein.
|Name||Catalog #||CAS #||Target Candidate|
|Arbidol HCl||331-11756||131707-23-8||Viral spike glycoprotein for binding to host cell receptor ACE2|
|Lopinavir||331-11643||192725-17-0||Coronavirus main protease 3CLpro|
|Ribavirin||331-10301||36791-04-5||RNA-dependent RNA polymerase|
|Chloroquine diphosphate||331-11962||54-05-7||Malaria (endosome/ACE2)|
|Nitazoxanide||331-11871||55981-09-4||Viral protein expression|
|Camostat mesilate||332-10779||59721-29-8||Transmembrane protease, serine 2, primes S protein to facilitate its binding to ACE2|
|Hydroxychloroquine Sulfate||331-21357||747-36-4||Malaria (endosome/ACE2)|
|Baricitinib Phosphate||332-10769||1187595-84-1||JAK kinase that regulate the inflammatory processes|